Racial Disparities Seen in Trials Supporting FDA Approvals for Multiple Myeloma
Black and Hispanic patients appear to be underrepresented in global clinical trials supporting FDA approval of multiple myeloma drugs.
Hematologic Cancers
Mitoxantrone and Clofarabine Reinduction for Pediatric Patients With Leukemia
Researchers sought to determine whether a reinduction therapy approach using mitoxantrone with clofarabine would be safe and effective for pediatric patients with leukemia.
Delays in Initiation of Revaccination in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
Initiation of revaccination appears to be delayed for a significant portion of pediatric patients following allo-HSCT.
Real-World Outcomes of Tisagenlecleucel in Patients Younger Than 3 Years With Acute Lymphoblastic Leukemia
Real-world data confirmed the efficacy and safety profiles of tisagenlecleucel in patients with relapsed/refractory ALL younger than 3 years old.
Long-Term Mortality Rates Elevated for Adolescent, Young Adult Leukemia Survivors
Survival for adolescent and young adult leukemia survivors remained below the general population at up to 30 years of follow-up.
AYA Cancer Survivors Twice As Likely to Die From Second Cancer
The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.
Younger Cancer Patients May Be at High Risk of Death From COVID-19
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
Frontline Daratumumab Improves Progression-Free Survival in High-Risk Multiple Myeloma
The addition of daratumumab resulted in a 41% reduction in the risk of disease progression or death.
Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma
Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes.
Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
- Loading...
Loading...
Next post in Tandem Meetings 2022
Loading... 
Loading...